Department of Pathology, University of Alabama, Birmingham, AL 35294-0019, USA.
Eur J Cancer. 2010 May;46(7):1283-9. doi: 10.1016/j.ejca.2010.02.023. Epub 2010 Mar 19.
Re-expression of KISS1 in tumor cell lines allows all antecedent steps of metastasis, but prevents colonization of secondary sites. Because tumor cells have already disseminated by the time of cancer diagnosis, KISS1 may represent a new opportunity for therapeutic intervention. Moreover, numerous clinical reports demonstrate that a loss or reduction of KISS1 expression in different human cancers inversely correlates with tumor progression, metastasis, and survival. Taken together, these observations compel the hypothesis that KISS1 could be of tremendous utility in controlling metastasis in a therapeutic context. In this review, we highlight some key findings from preclinical and clinical studies and discuss strategies whereby KISS1 may be exploited clinically to treat metastases.
在肿瘤细胞系中重新表达 KISS1 允许转移的所有前期步骤，但阻止了次级部位的定植。由于在癌症诊断时肿瘤细胞已经扩散，因此 KISS1 可能代表了治疗干预的新机会。此外，大量临床报告表明，在不同的人类癌症中，KISS1 的缺失或减少与肿瘤进展、转移和生存呈负相关。综上所述，这些观察结果促使人们假设 KISS1 在治疗上控制转移方面可能具有巨大的作用。在这篇综述中，我们强调了一些临床前和临床研究的关键发现，并讨论了如何利用 KISS1 来治疗转移的策略。
